MAAT INDEX

CLAIM #33396 · Intuitive Surgical Inc (ISRG) · 2026Q1 earnings call · Apr 21, 2026 · due Dec 31, 2026

We now forecast other income, which is comprised mostly of interest income, to total between $315 million and $335 million due primarily to lower average cash balances following share repurchase activity in Q1.

Daniel Connally · VP Investor Relations

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Other income (non-GAAP), full fiscal year 2026

It came true if: Between $315 million and $335 million

Where: Company non-GAAP financial results / income statement (10-K or Q4 earnings release)

In context

rofit margin to be within a range of 67.5% and 68.5% of revenue, which now reflects 100 basis points of impact from tariffs as well as higher input costs in other areas, including freight and semiconductor memory. Other factors for the year include faster growth of newer products in daVinci 5 and Ion, modest incremental depreciation from recent facility expansion and the impact from higher da Vinci system upgrades, partially offset by cost reductions. Our actual non-GAAP gross profit margin will vary quarter-to-quarter depending largely on product, regional and trade-in mix and pricing. In regard to operating expenses, we now expect non-GAAP operating expense growth to be between 11% and 14%. We continue to estimate noncash stock compensation expense between $890 million and $920 million. We now forecast other income, which is comprised mostly of interest income, to total between $315 million and $335 million due primarily to lower average cash balances following share repurchase activity in Q1. With regard to income tax, we continue to expect our non-GAAP income tax rate to be between 22% and 23% of pretax income. That concludes our prepared remarks. We will now open the call to your questions. Operator: [Operator Instructions] Our first question will come from the line of Travis Steed with Bank of America. Travis Steed: Congrats on a good quarter. Maybe to start, I kind of want to talk a little bit about some of the future. You talked a lot about data and digital infrastructure, augmented dexterity. Just kind of curious how you see the digital and data road map for Intuitive. And there's also some hints on biopsy and the ROSE acquisition. So I'd love to kind of hear your big picture view of how that kind of plays out and anything you can say on timing? David Rosa: Yes. Happy to

Verify independently

SEC filings for ISRG · Claim quote is verbatim from the 2026Q1 earnings call.